TLDR XRP whales accumulated 340 million tokens over two weeks, bringing total holdings to 7.84 billion XRP Bloomberg analysts raised XRP spot ETF approval odds to 95% following synchronized SEC filings from major firms XRP futures launched on Coinbase Derivatives and CME, meeting SEC’s six-month requirement for ETF approval XRP market cap reached $132 billion [...] The post XRP Price Prediction: Smart Money Accumulate 340M Tokens as ETF Approval Odds Hit 95% appeared first on CoinCentral.TLDR XRP whales accumulated 340 million tokens over two weeks, bringing total holdings to 7.84 billion XRP Bloomberg analysts raised XRP spot ETF approval odds to 95% following synchronized SEC filings from major firms XRP futures launched on Coinbase Derivatives and CME, meeting SEC’s six-month requirement for ETF approval XRP market cap reached $132 billion [...] The post XRP Price Prediction: Smart Money Accumulate 340M Tokens as ETF Approval Odds Hit 95% appeared first on CoinCentral.

XRP Price Prediction: Smart Money Accumulate 340M Tokens as ETF Approval Odds Hit 95%

TLDR

  • XRP whales accumulated 340 million tokens over two weeks, bringing total holdings to 7.84 billion XRP
  • Bloomberg analysts raised XRP spot ETF approval odds to 95% following synchronized SEC filings from major firms
  • XRP futures launched on Coinbase Derivatives and CME, meeting SEC’s six-month requirement for ETF approval
  • XRP market cap reached $132 billion in Q2 2025, ranking fourth among cryptocurrencies with 8.5% growth
  • Price currently trades around $2.8 with key resistance at $3 and support at $2.8

XRP has captured attention from institutional investors as whale wallets continue massive accumulation while regulatory developments point toward imminent ETF approval in the United States.

Large holders have purchased 340 million XRP tokens over the past two weeks, according to data tracked by analyst @ali_charts. These wallets, containing between 10 million and 100 million XRP each, now hold approximately 7.84 billion tokens total.

The accumulation comes as XRP trades around $2.8, with whales buying consistently while retail traders remain uncertain about price direction. This pattern often indicates institutional knowledge of upcoming developments before broader market recognition.

xrp priceXRP Price

Regulatory Pathway Clears for ETF Approval

Seven major financial firms submitted synchronized S-1 filings with the SEC on August 22, including Canary, Coinshares, Franklin, 21Shares, Wisdomtree, and Bitwise. Grayscale also filed to convert its existing XRP Trust into a spot ETF.

Bloomberg analysts Eric Balchunas and James Seyffart raised their XRP ETF approval probability to 95%. The clustering of submissions suggests active dialogue between fund managers and regulators.

XRP futures trading began on Coinbase Derivatives Exchange on April 21, 2025, followed by CME Group on May 18, 2025. These listings satisfy the SEC’s requirement for more than six months of futures tracking before approving spot ETFs.

The SEC’s new listing standards for crypto ETPs became public in July, providing clear guidelines for approval. XRP now meets these requirements, positioning it for potential ETF launch in fall 2025.

Ripple CEO Brad Garlinghouse previously called an XRP ETF “inevitable,” a view that appears increasingly supported by regulatory developments.

XRP Price Prediction

XRP’s market capitalization grew 8.5% in Q2 2025, reaching $132 billion and maintaining its fourth-place ranking among cryptocurrencies. This growth occurred alongside expansion of the XRP Ledger ecosystem.

Recent price action shows resilience despite futures market cooling. Open interest dropped from over $3.5 billion, indicating leverage reduction without corresponding price crashes.

Source: TradingView

The $2.8 level serves as current support, while $3 represents immediate resistance. Technical analysis suggests potential targets between $3.20 and $3.40 if buyers break through resistance.

Failure to hold $2.8 support could lead to testing the $2.60-$2.70 range before finding stronger foundation.

XRPL ecosystem growth includes new stablecoins and tokenized assets reaching record levels. Ripple’s RLUSD stablecoin surged 49.4% during Q2, closing with $65.9 million market cap.

Real-world assets on XRPL hit $131.6 million market cap, driven by tokenized treasuries, commercial paper, and real estate projects.

The XRPL EVM sidechain launched on June 30, adding smart contract functionality to the network.

Current whale accumulation patterns historically precede major price movements. The combination of regulatory clarity, institutional buying, and reduced speculative activity creates conditions for potential breakouts.

XRP futures contracts on major exchanges now provide the regulatory foundation needed for ETF approval, with multiple fund managers positioned to launch products pending SEC authorization.

The post XRP Price Prediction: Smart Money Accumulate 340M Tokens as ETF Approval Odds Hit 95% appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26